ABSTRACT
Objective Type 1 diabetes (T1D) screening programmes testing islet autoantibodies (IAbs) in childhood can reduce life-threatening diabetic ketoacidosis. General population screening is required to detect the majority of children with T1D, since in >85% there is no family history. Age 3-5 has been proposed as an optimal age for a single screen approach.
Design Capillary samples were collected from children attending their pre-school vaccination and analysed for IAbs to insulin, glutamic acid decarboxylase, islet antigen-2, and zinc transporter 8, using Radiobinding/Luciferase Immunoprecipitation Systems assays. Acceptability was assessed using semi-structured interviews and open-ended postcard questionnaires with parents.
Setting Two primary care practices in Oxfordshire, UK.
Main outcome measures The ability to collect capillary blood to test IAbs in children at the routine pre-school vaccination (3.5-4 years).
Results Of 134 parents invited, 66 (49%) were recruited (median age 3.5y (IQR 3. 4-3.6), 26(39.4%) male); 63 provided a sample (97% successfully). Parents (n=15 interviews, n=29 postcards) were uniformly positive about screening aligned to vaccination and stated they would have been less likely to take part had screening been a separate visit. Themes identified included preparedness for T1D, and the long-term benefit outweighing short-term upset. The perceived volume of the capillary sample was a potential concern and needs optimising.
Conclusions Capillary IAb testing is a possible method to screen children for T1D. Aligning collection to the pre-school vaccination visit can be convenient for families and allows a universal approach without the need for an additional visit.
What is already known on this topic?Screening children for type 1 diabetes by measuring islet autoantibodies (IAbs) may reduce life-threatening diabetic ketoacidosis. The optimal age for screening children at a single timepoint has been proposed as age 3-5. Routine immunisations are given at a similar age.
What does this study add?Aligning IAb testing with the pre-school vaccination visit (age 3.5-4y) is feasible and acceptable. Potential barriers and facilitators of this approach are explored.
How this study might affect research, practice or policy?The routine vaccination programme is a potential opportunity to screen children for future type 1 diabetes, offering improved engagement and potentially reducing the costs associated with a screening programme; all of which need exploration in a large and definitive study.
Competing Interest Statement
R.E.J.B has been as an independent advisor to Provention Bio. J.A.T. is a member of the Scientific Advisory Boards of GSK, Vesalius Therapeutics, Precion and Qlife. C.M.D has lectured for or been involved as an advisor to the following companies: Novo Nordisk, Sanofi-genzyme, Janssen, Servier, Lilly, AstraZeneca, Provention Bio, UCB, MSD, Vielo Bio, Avotres, Worg, Novartis; holds a patent jointly with Midatech plc.
Funding Statement
This study was supported by grants from the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) and from an NIHR Programme Development Grant (PDG). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. For the purpose of Open Access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising. R.E.J.B., J.T. and C.S. are funded through the NIHR PDG. R.E.J.B., J.A.T. and C.S. are also funded through the JDRF/Wellcome Strategic Award (4-SRA-2017-473-A-N; 107212/A/15/Z). LIPS testing was supported by a JDRF grant to K.M.G. (2-SRA-2020-964-S-B).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Northwest Preston Research Ethics Committee (ref 21/NW/0340) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Claire Scudder and Julia Townson share joint first authorship.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
